Limitation of Myocardial Infarction Following Thrombolysis in Acute - LIMIT AMI

Description:

The LIMIT AMI trial was designed to determine the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the B2 integrin adhesion receptors (rhuMAb CD18), in acute MI patients treated with a thrombolytic agent.